1990 年至 2021 年与 1 型糖尿病相关的髋部骨折负担的全球和地区估计值。

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jing Li BS, Hao-Liang Cui BS, Dan-Dan Xie MSc, Qin-Yi Wang MSc, Chuo Luo MSc, Lin Tian BS, Lin-Ke Shi BS, Zhi-Feng Sheng MD
{"title":"1990 年至 2021 年与 1 型糖尿病相关的髋部骨折负担的全球和地区估计值。","authors":"Jing Li BS,&nbsp;Hao-Liang Cui BS,&nbsp;Dan-Dan Xie MSc,&nbsp;Qin-Yi Wang MSc,&nbsp;Chuo Luo MSc,&nbsp;Lin Tian BS,&nbsp;Lin-Ke Shi BS,&nbsp;Zhi-Feng Sheng MD","doi":"10.1111/dom.15970","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To assess the global and regional burden of hip fractures associated with type 1 diabetes (T1D) from 1990 to 2021.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>The population attributable fraction was calculated by combining the published risk ratio with T1D prevalence (age ≥ 20 years) from the Global Burden of Disease study to estimate the T1D-associated hip-fracture burden. Trends were assessed using the age-standardized incidence rate (ASIR) and estimated annual percentage change (EAPC).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The global incidence of T1D-related hip fractures was 290 180 in 2021 with an ASIR of 3.96 (95% confidence interval: 1.92-5.87) per 100 000 population and a male-to-female ratio of 0.54. At the super-regional level, the highest incidence (204 610) and ASIR (13.09 per 100 000 population; 6.40-25.53) were observed in high-income regions, in particular in Australasia and Western Europe. Notably, Australasia exhibited the highest EAPC, 2.90% in T1D-associated ASIR, followed by East Asia (2.73%). The incidence among those aged 45-64 years grew significantly in 14 regions over the past decade. Nationally, the ASIR increased in 166 countries from 1990 to 2021.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>High-income regions experienced the greatest burden of T1D-associated hip fracture, while Australasia and East Asia witnessed the largest increase over the last 32 years. Prioritizing the promotion of T1D treatment and hip-fracture screening for middle-aged females living with T1D is crucial in these regions.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"26 12","pages":"5960-5970"},"PeriodicalIF":5.7000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021\",\"authors\":\"Jing Li BS,&nbsp;Hao-Liang Cui BS,&nbsp;Dan-Dan Xie MSc,&nbsp;Qin-Yi Wang MSc,&nbsp;Chuo Luo MSc,&nbsp;Lin Tian BS,&nbsp;Lin-Ke Shi BS,&nbsp;Zhi-Feng Sheng MD\",\"doi\":\"10.1111/dom.15970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To assess the global and regional burden of hip fractures associated with type 1 diabetes (T1D) from 1990 to 2021.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>The population attributable fraction was calculated by combining the published risk ratio with T1D prevalence (age ≥ 20 years) from the Global Burden of Disease study to estimate the T1D-associated hip-fracture burden. Trends were assessed using the age-standardized incidence rate (ASIR) and estimated annual percentage change (EAPC).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The global incidence of T1D-related hip fractures was 290 180 in 2021 with an ASIR of 3.96 (95% confidence interval: 1.92-5.87) per 100 000 population and a male-to-female ratio of 0.54. At the super-regional level, the highest incidence (204 610) and ASIR (13.09 per 100 000 population; 6.40-25.53) were observed in high-income regions, in particular in Australasia and Western Europe. Notably, Australasia exhibited the highest EAPC, 2.90% in T1D-associated ASIR, followed by East Asia (2.73%). The incidence among those aged 45-64 years grew significantly in 14 regions over the past decade. Nationally, the ASIR increased in 166 countries from 1990 to 2021.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>High-income regions experienced the greatest burden of T1D-associated hip fracture, while Australasia and East Asia witnessed the largest increase over the last 32 years. Prioritizing the promotion of T1D treatment and hip-fracture screening for middle-aged females living with T1D is crucial in these regions.</p>\\n </section>\\n </div>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"26 12\",\"pages\":\"5960-5970\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dom.15970\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15970","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估1990年至2021年与1型糖尿病(T1D)相关的髋部骨折的全球和地区负担:通过将全球疾病负担研究(Global Burden of Disease)中已公布的风险比与T1D患病率(年龄≥20岁)相结合,计算出人口可归因部分,从而估算出与T1D相关的髋部骨折负担。使用年龄标准化发病率(ASIR)和估计年百分比变化(EAPC)评估了发病趋势:结果:2021 年全球 T1D 相关髋部骨折发病率为 290 180 例,年龄标准化发病率为每 10 万人 3.96 例(95% 置信区间:1.92-5.87),男女比例为 0.54。在超地区一级,高收入地区的发病率(204 610 例)和 ASIR(每 10 万人 13.09 例;6.40-25.53)最高,尤其是在澳大拉西亚和西欧。值得注意的是,在与 T1D 相关的 ASIR 中,澳大拉西亚的 EAPC 最高,为 2.90%,其次是东亚(2.73%)。在过去十年中,14 个地区 45-64 岁人群的发病率显著增加。从 1990 年到 2021 年,全国有 166 个国家的 ASIR 出现增长:结论:在过去的 32 年中,高收入地区承受了与 T1D 相关的髋部骨折的最大负担,而澳大拉西亚和东亚地区的增幅最大。在这些地区,优先推广 T1D 治疗和对患有 T1D 的中年女性进行髋部骨折筛查至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021

Aim

To assess the global and regional burden of hip fractures associated with type 1 diabetes (T1D) from 1990 to 2021.

Materials and Methods

The population attributable fraction was calculated by combining the published risk ratio with T1D prevalence (age ≥ 20 years) from the Global Burden of Disease study to estimate the T1D-associated hip-fracture burden. Trends were assessed using the age-standardized incidence rate (ASIR) and estimated annual percentage change (EAPC).

Results

The global incidence of T1D-related hip fractures was 290 180 in 2021 with an ASIR of 3.96 (95% confidence interval: 1.92-5.87) per 100 000 population and a male-to-female ratio of 0.54. At the super-regional level, the highest incidence (204 610) and ASIR (13.09 per 100 000 population; 6.40-25.53) were observed in high-income regions, in particular in Australasia and Western Europe. Notably, Australasia exhibited the highest EAPC, 2.90% in T1D-associated ASIR, followed by East Asia (2.73%). The incidence among those aged 45-64 years grew significantly in 14 regions over the past decade. Nationally, the ASIR increased in 166 countries from 1990 to 2021.

Conclusions

High-income regions experienced the greatest burden of T1D-associated hip fracture, while Australasia and East Asia witnessed the largest increase over the last 32 years. Prioritizing the promotion of T1D treatment and hip-fracture screening for middle-aged females living with T1D is crucial in these regions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信